Navigation Links
NuvOx Pharma Begins Clinical Trial to Treat Brain Cancer
Date:8/7/2014

Tucson, AZ (PRWEB) August 07, 2014

NuvOx Pharma, a privately held biotechnology company based in Tucson, Arizona, focused on developing a nanotechnology platform for reversing conditions with decreased oxygen announced that on July 14th, it began a Phase Ib clinical trial of its new drug NVX-108 in patients with glioblastoma, a deadly form of brain cancer.

Glioblastoma multiforme (GBM), according to the Central Brain Tumor Registry, affects about 10,300 patients per year in the US. Average survival is only about 12-months following standard therapy, which involves surgery followed by radiation and chemotherapy. GBM, like many other forms of cancer, is known to have low oxygen (hypoxia). Hypoxia adversely affects the response of tumors to radiation therapy and NVX-108 has been shown to raise tumor oxygen levels and improve the response to radiation therapy. The clinical trial is being performed at Monash University in Melbourne Australia. GBM patients who have residual tumor after surgery are receiving an IV dose of NVX-108 during each of the 30 fractions of radiation over a 6-week period. Up to about 25 patients will be treated in the trial. The primary end-point of the trial is safety, but the study will also determine the recommended dose for the drug and provide data on the 6-month survival of the patients. After completion of the trial NuvOx plans to file an investigational new drug application with the FDA and perform a Phase IIb trial in the US.

“We are very excited about moving NVX-108 into the first therapeutic trial. The parent compound, dodecafluoropentane, was previously studied as a contrast agent and was shown to be safe. Due to market considerations it was never launched as a contrast agent. We own that regulatory data and the FDA has agreed that we can reference it in support of clinical development to treat cancer,” said Evan Unger, MD, President and CEO of NuvOx.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12071710.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System
2. Sanuvox Releases the Aseptix Dual UV Sterilization System to Help Reduce Nosocomial (HAI) Infections in Hospital Environments
3. URAC Seeks Public Comments on Revised Specialty Pharmacy and Mail Service Pharmacy Accreditation Standards and Measures
4. Good Neighbor Pharmacy’s 2014 ThoughtSpot Inspires Independent Pharmacists to Transform Their Businesses
5. Harry Race Pharmacy Named 2014 Good Neighbor Pharmacy of the Year
6. Community pharmacist intervention boosts drug adherence, reduces health-care costs
7. Pharmaceuticals Wholesaling in Australia Industry Market Research Report Now Updated by IBISWorld
8. West Coast University Launches New Doctorate of Pharmacy Program
9. PharmaVOICE Honors Five PHCG Leaders Among 100 Healthcare Visionaries
10. US Pharmaceutical Packaging Products Worth $22.1 Billion by 2018 Says a New Research Report at LifeScienceIndustryResearch.com
11. Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Dc (PRWEB) , ... January 23, 2017 , ... ... American University is taught by healthcare management and evaluation leaders with decades of ... fee-for-service to pay-for-value in the United States healthcare system, there is a renewed ...
(Date:1/23/2017)... ... 23, 2017 , ... Moisture measurement is a necessary process ... paramount to success. Selecting an inappropriate measurement method can cause costly errors, and ... same equipment. Rare or expensive substances are wasted and production may even be ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... gynecological care and gynecological services for women of all ages. The ... a wide variety of reproductive services from routine health screenings to diagnosing and ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating ... of Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the ... years, a preacher for over nineteen, a pastor for over fifteen years. He is ...
(Date:1/22/2017)... ... 2017 , ... Medical lab testing through hospitals and other traditional ... test will take days to arrive to the end customer, having to travel through ... their lab tests, bypassing the cost and delay of traditional means. Now all employees ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Alberta , January 23, 2017 ... del riñón (r enal) y ... sola dosis de a pabetalone    ... hoy los resultados preliminares de un ensayo en fase ... con discapacidad de riñón (renal) severa. Los datos demostraron ...
(Date:1/23/2017)... , January 23, 2017 Stock-Callers.com today ... Inc. (NASDAQ: CPRX ), Sophiris Bio Inc. (NASDAQ: ... MNTA ), and Agile Therapeutics Inc. (NASDAQ: AGRX ... turned somewhat lower in late trade on Friday, January 20 ... about 0.3%, while shares of health care companies in the ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are factors ... BCC Research reveals in its new report that markets in developing ... strong growth due to rising government healthcare spending, increased levels of healthcare ... Reading ... BCC ...
Breaking Medicine Technology: